Sign in or create an account to add this stock to your watchlist.
About Nabriva Therapeutics (NASDAQ:NBRV)
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection. The company is also developing BC-7013, a semi-synthetic compound derived from pleuromutilin, which has completed a Phase 1 clinical trial for the treatment of Gram-positive infections, including uncomplicated skin and skin structure infections. In addition, it is developing lefamulin for use in the treatment of ventilator-associated bacterial pneumonia or hospital-acquired bacterial pneumonia and sexually transmitted infections. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NBRV
CUSIPN/A
Phone610-816-6640
Debt
Debt-to-Equity RatioN/A
Current Ratio8.66
Quick Ratio8.66
Price-To-Earnings
Trailing P/E Ratio-1.78
Forward P/E Ratio-2.49
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.32 million
Price / Sales30.58
Cash FlowN/A
Price / CashN/A
Book Value$2.41 per share
Price / Book1.84
Profitability
EPS (Most Recent Fiscal Year)($2.49)
Net Income$-74,350,000.00
Net Margins-600.34%
Return on Equity-79.30%
Return on Assets-66.97%
Miscellaneous
Employees88
Outstanding Shares36,720,000
Nabriva Therapeutics (NASDAQ:NBRV) Frequently Asked Questions
What is Nabriva Therapeutics' stock symbol?
Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV."
How were Nabriva Therapeutics' earnings last quarter?
Nabriva Therapeutics (NASDAQ:NBRV) released its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported ($0.36) EPS for the quarter, beating the Zacks' consensus estimate of ($0.59) by $0.23. The biotechnology company earned $7.55 million during the quarter, compared to the consensus estimate of $1.27 million. Nabriva Therapeutics had a negative net margin of 600.34% and a negative return on equity of 79.30%. View Nabriva Therapeutics' Earnings History.
When is Nabriva Therapeutics' next earnings date?
What price target have analysts set for NBRV?
8 brokers have issued 1-year price targets for Nabriva Therapeutics' shares. Their predictions range from $10.00 to $24.00. On average, they expect Nabriva Therapeutics' stock price to reach $17.75 in the next year. View Analyst Ratings for Nabriva Therapeutics.
What are Wall Street analysts saying about Nabriva Therapeutics stock?
Here are some recent quotes from research analysts about Nabriva Therapeutics stock:
- 1. Needham & Company LLC analysts commented, "Nabriva reported 1Q18 financial results today and we spoke w/ mgmt for an update. Mgmt reiterated guidance for top-line results from the second of two Phase 3 trials of lead antibiotic lefamulin in Community Pneumonia (CABP) in 2Q18. We continue to expect a positive outcome and reiterate BUY rating. We believe the opportunity for lefamulin in Community Pneumonia is misunderstood and underappreciated by investors. We acknowledge challenges for antibiotics within the hospital, but believe oral lefamulin can be relevant in the large outpatient community setting." (5/8/2018)
- 2. According to Zacks Investment Research, "Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics' medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics' lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP). " (4/4/2018)
- 3. HC Wainwright analysts commented, "Updated Results from SITC Confirm IMO-2125 Clinical Benefit; Reiterate Buy IMO-2125 activates innate immune response against tumor. Last week we attended the annual meeting for Society for Immunotherapy of Cancer (SITC) held in National Harbor, Maryland. At the conference, Dr. Haymaker from MD Anderson Cancer Center presented additional results from the ongoing Phase 1/2 clinical study of IMO-2125, a TLR9 agonist from Idera. Recall, IMO-2125 is being investigated as a combinational therapy together with Bristol-Myers Squibb’s (BMY; not rated) Yervoy (ipilimumab) for the treatment of PD-1 refractory melanoma. Previously, it was reported that the combination of IMO-2125 and ipilimumab achieved an overall response rate (ORR) of 44%. The updated results presented at the SITC conference included an additional patient with confirmed response, which improved the ORR from the study to 50% (5 out of 10 patients). Importantly, gene expression analysis in patients’ tumor biopsies, taken 24 hours after IMO-2125 injections, suggests that IMO-2125 upregulates interferon-alpha production, promotes dendritic cells maturation and the inflow of macrophages at the tumor site. Moreover, considering that ipilimumab has not yet been administered at the time of the biopsy, the observed activation of immune system can be fully attributed to IMO-2125, rather than the drug combination. In our view, these results provide additional confidence in the clinical activity of IMO-2125 and potential success of the planned Phase 3 study, which is expected to start in 1Q18." (11/16/2017)
- 4. Cantor Fitzgerald analysts commented, "Yesterday, after market close, Nabriva announced that Elyse Seltzer, M.D., is resigning as CMO effective 9/30/2017." (9/1/2017)
Who are some of Nabriva Therapeutics' key competitors?
Some companies that are related to Nabriva Therapeutics include Aduro BioTech (ADRO), Five Prime Therapeutics (FPRX), Rigel Pharmaceuticals (RIGL), Ziopharm Oncology (ZIOP), ChemoCentryx (CCXI), Odonate Therapeutics (ODT), Lannett (LCI), BeyondSpring (BYSI), Keryx Biopharmaceuticals (KERX), Stemline Therapeutics (STML), Prothena (PRTA), Aclaris Therapeutics (ACRS), Akebia Therapeutics (AKBA), AC Immune (ACIU) and CannTrust (CNTTF).
Who are Nabriva Therapeutics' key executives?
Nabriva Therapeutics' management team includes the folowing people:
- Dr. Colin Broom, CEO, Interim Chief Medical Officer & Director (Age 62)
- Mr. Gary L. Sender, Chief Financial Officer (Age 56)
- Mr. Steven P. Gelone Pharm. D, Chief Scientific Officer (Age 50)
- Mr. Thomas Lembck, Chief Information Officer
- Mr. David Garrett, Head of Investor Relations, VP & Corp. Controller
Has Nabriva Therapeutics been receiving favorable news coverage?
News headlines about NBRV stock have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Nabriva Therapeutics earned a news impact score of 0.24 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 47.10 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are Nabriva Therapeutics' major shareholders?
Nabriva Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (2.24%), Acuta Capital Partners LLC (1.52%), BlackRock Inc. (1.23%), Prosight Management LP (0.66%), Dimensional Fund Advisors LP (0.30%) and Trexquant Investment LP (0.13%). Company insiders that own Nabriva Therapeutics stock include Colin Md Broom, Francesco Maria Lavino, Gary Sender, George Harrison Talbot, Hbm Healthcare Investments (Ca, Robert Crotty, Stephen W Webster and Vivo Capital Viii, Llc. View Institutional Ownership Trends for Nabriva Therapeutics.
Which major investors are selling Nabriva Therapeutics stock?
NBRV stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Prosight Management LP, Millennium Management LLC and Acuta Capital Partners LLC. Company insiders that have sold Nabriva Therapeutics company stock in the last year include George Harrison Talbot and Hbm Healthcare Investments (Ca. View Insider Buying and Selling for Nabriva Therapeutics.
Which major investors are buying Nabriva Therapeutics stock?
NBRV stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Dimensional Fund Advisors LP, Trexquant Investment LP, DRW Securities LLC and JPMorgan Chase & Co.. Company insiders that have bought Nabriva Therapeutics stock in the last two years include Colin Md Broom, Francesco Maria Lavino, Gary Sender, Robert Crotty, Stephen W Webster and Vivo Capital Viii, Llc. View Insider Buying and Selling for Nabriva Therapeutics.
How do I buy shares of Nabriva Therapeutics?
Shares of NBRV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nabriva Therapeutics' stock price today?
One share of NBRV stock can currently be purchased for approximately $4.43.
How big of a company is Nabriva Therapeutics?
Nabriva Therapeutics has a market capitalization of $165.96 million and generates $5.32 million in revenue each year. The biotechnology company earns $-74,350,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Nabriva Therapeutics employs 88 workers across the globe.
How can I contact Nabriva Therapeutics?
Nabriva Therapeutics' mailing address is 56 FITZWILLIAM SQUARE, DUBLIN L2, 19406. The biotechnology company can be reached via phone at 610-816-6640 or via email at [email protected]
MarketBeat Community Rating for Nabriva Therapeutics (NBRV)
MarketBeat's community ratings are surveys of what our community members think about Nabriva Therapeutics and other stocks. Vote "Outperform" if you believe NBRV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBRV will underperform the S&P 500 over the long term. You may vote once every thirty days.
Nabriva Therapeutics (NASDAQ:NBRV) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for Nabriva Therapeutics in the last 12 months. Their average twelve-month price target is $17.75, suggesting that the stock has a possible upside of 300.68%. The high price target for NBRV is $24.00 and the low price target for NBRV is $10.00. There are currently 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $17.75 | $17.6250 | $18.7143 | $20.4286 |
| Price Target Upside: | 300.68% upside | 226.99% upside | 211.90% upside | 268.75% upside |
Nabriva Therapeutics (NASDAQ:NBRV) Consensus Price Target History
Nabriva Therapeutics (NASDAQ:NBRV) Analyst Ratings History
Show:
(Data available from 5/27/2016 forward)
Nabriva Therapeutics (NASDAQ:NBRV) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Nabriva Therapeutics (NASDAQ NBRV) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 2.75%
Institutional Ownership Percentage: 68.88%
Nabriva Therapeutics (NASDAQ NBRV) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/23/2018 | Gary Sender | CFO | Buy | 2,000 | $4.57 | $9,140.00 | 6,200 |  |
| 5/23/2018 | Robert Crotty | General Counsel | Buy | 10,000 | $4.48 | $44,800.00 | 10,000 | |
| 5/23/2018 | Stephen W Webster | Director | Buy | 8,000 | $4.59 | $36,720.00 | 8,000 | |
| 11/29/2017 | Francesco Maria Lavino | Insider | Buy | 1,569 | $6.29 | $9,869.01 | | |
| 9/22/2017 | Colin Md Broom | CEO | Buy | 2,588 | $8.35 | $21,609.80 | 87,151 | |
| 9/22/2017 | Gary Sender | CFO | Buy | 2,000 | $8.21 | $16,420.00 | 4,200 | |
| 9/18/2017 | Vivo Capital Viii, Llc | Major Shareholder | Buy | 52,631 | $9.46 | $497,889.26 | | |
| 9/14/2017 | Hbm Healthcare Investments (Ca | Major Shareholder | Sell | 36,608 | $8.56 | $313,364.48 | | |
| 8/31/2017 | Hbm Healthcare Investments (Ca | Major Shareholder | Sell | 639 | $9.50 | $6,070.50 | 2,370,735 | |
| 8/8/2017 | Hbm Healthcare Investments (Ca | Major Shareholder | Sell | 19,803 | $10.50 | $207,931.50 | 2,373,387 | |
| 8/7/2017 | Hbm Healthcare Investments (Ca | Major Shareholder | Sell | 17,790 | $10.50 | $186,795.00 | 2,373,387 | |
| 7/28/2017 | Hbm Healthcare Investments (Ca | Major Shareholder | Sell | 6,585 | $10.51 | $69,208.35 | 2,391,177 | |
| 7/24/2017 | Hbm Healthcare Investments (Ca | Major Shareholder | Sell | 160 | $10.50 | $1,680.00 | 2,397,762 | |
| 7/20/2017 | Hbm Healthcare Investments (Ca | Major Shareholder | Sell | 44,231 | $10.50 | $464,425.50 | 2,421,367 | |
| 7/18/2017 | Hbm Healthcare Investments (Ca | Major Shareholder | Sell | 69,854 | $10.51 | $734,165.54 | 2,490,952 | |
| 7/13/2017 | Hbm Healthcare Investments (Ca | Major Shareholder | Sell | 57,175 | $10.53 | $602,052.75 | 2,565,661 | |
| 7/7/2017 | Hbm Healthcare Investments (Ca | Major Shareholder | Sell | 2,695 | $10.52 | $28,351.40 | 2,569,315 | |
| 7/3/2017 | Hbm Healthcare Investments (Ca | Major Shareholder | Sell | 13,127 | $10.94 | $143,609.38 | 2,583,229 | |
| 6/30/2017 | Hbm Healthcare Investments (Ca | Major Shareholder | Sell | 1,775 | $10.94 | $19,418.50 | 2,583,229 | |
| 6/29/2017 | Hbm Healthcare Investments (Ca | Major Shareholder | Sell | 8,558 | $10.96 | $93,795.68 | 2,591,396 | |
| 6/19/2017 | George Harrison Talbot | Director | Sell | 170 | $93.18 | $15,840.60 | 3,249 | |
| 5/30/2017 | George Harrison Talbot | Director | Sell | 210 | $101.26 | $21,264.60 | 3,449 | |
| 5/25/2017 | George Harrison Talbot | Director | Sell | 325 | $100.56 | $32,682.00 | 3,854 | |
| 5/16/2017 | George Harrison Talbot | Director | Sell | 200 | $102.44 | $20,488.00 | 3,351 | |
| 5/15/2017 | George Harrison Talbot | Director | Sell | 50 | $101.50 | $5,075.00 | 3,351 | |
| 4/28/2017 | Hbm Healthcare Investments (Ca | Major Shareholder | Sell | 15,939 | $11.02 | $175,647.78 | 2,609,192 | |
| 4/21/2017 | Hbm Healthcare Investments (Ca | Major Shareholder | Sell | 2,622 | $11.04 | $28,946.88 | 2,609,901 | |
| 4/20/2017 | Hbm Healthcare Investments (Ca | Major Shareholder | Sell | 23,932 | $11.11 | $265,884.52 | 2,624,633 | |
| 4/13/2017 | Hbm Healthcare Investments (Ca | Major Shareholder | Sell | 32,831 | $11.24 | $369,020.44 | 2,660,689 | |
| 4/10/2017 | Hbm Healthcare Investments (Ca | Major Shareholder | Sell | 90,594 | $10.96 | $992,910.24 | 269,371 | |
(Data available from 1/1/2013 forward)
Nabriva Therapeutics (NASDAQ NBRV) News Headlines
| Source: |
|
Nabriva Therapeutics (NASDAQ:NBRV) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Nabriva Therapeutics (NASDAQ:NBRV) Income Statement, Balance Sheet and Cash Flow Statement
Nabriva Therapeutics (NASDAQ NBRV) Stock Chart for Sunday, May, 27, 2018
Loading chart…
